Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 427

1.

Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.

Pontali E, Sotgiu G, Tiberi S, Tadolini M, Visca D, D'Ambrosio L, Centis R, Spanevello A, Migliori GB.

Eur Respir J. 2018 Jul 4;52(1). pii: 1800934. doi: 10.1183/13993003.00934-2018. Print 2018 Jul. No abstract available.

PMID:
29903862
2.

Tuberculosis series.

Silva DR, Mello FCQ, Kritski A, Dalcolmo M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):71-72. doi: 10.1590/s1806-37562018000020001. Portuguese, English. No abstract available.

3.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Portuguese, English.

4.

Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy.

Carvalho ACC, Cardoso CAA, Martire TM, Migliori GB, Sant'Anna CC.

J Bras Pneumol. 2018 Apr;44(2):134-144. doi: 10.1590/s1806-37562017000000461. Portuguese, English.

5.

Eliminating tuberculosis in Latin America: making it the point.

Duarte R, Silva DR, Rendon A, Alves TG, Rabahi MF, Centis R, Kritski A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):73-76. doi: 10.1590/s1806-37562017000000449. Portuguese, English. No abstract available.

6.

Predictors of mortality among intensive care unit patients coinfected with tuberculosis and HIV.

Ferreira MD, Neves CPD, Souza AB, Beraldi-Magalhães F, Migliori GB, Kritski AL, Cordeiro-Santos M.

J Bras Pneumol. 2018 Apr;44(2):118-124. doi: 10.1590/s1806-37562017000000316. Portuguese, English.

7.

Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium.

Abubakar I, Matteelli A, de Vries G, Zenner D, Cirillo DM, Lönnroth K, Popescu G, Barcellini L, Story A, Migliori GB.

Eur Respir J. 2018 May 10;51(5). pii: 1702604. doi: 10.1183/13993003.02604-2017. Print 2018 May. No abstract available.

PMID:
29748241
8.

ERS/ECDC Statement: European Union standards for tuberculosis care, 2017 update.

Migliori GB, Sotgiu G, Rosales-Klintz S, Centis R, D'Ambrosio L, Abubakar I, Bothamley G, Caminero JA, Cirillo DM, Dara M, de Vries G, Aliberti S, Dinh-Xuan AT, Duarte R, Midulla F, Solovic I, Subotic DR, Amicosante M, Correia AM, Cirule A, Gualano G, Kunst H, Palmieri F, Riekstina V, Tiberi S, Verduin R, van der Werf MJ.

Eur Respir J. 2018 May 17;51(5). pii: 1702678. doi: 10.1183/13993003.02678-2017. Print 2018 May.

PMID:
29678945
9.

Defining the best regimen to treat isoniazid-resistant tuberculosis.

Migliori GB, Tiberi S, Sotgiu G.

Lancet Respir Med. 2018 Apr;6(4):233-235. doi: 10.1016/S2213-2600(18)30079-1. No abstract available.

PMID:
29595499
10.

Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies.

Tiberi S, du Plessis N, Walzl G, Vjecha MJ, Rao M, Ntoumi F, Mfinanga S, Kapata N, Mwaba P, McHugh TD, Ippolito G, Migliori GB, Maeurer MJ, Zumla A.

Lancet Infect Dis. 2018 Jul;18(7):e183-e198. doi: 10.1016/S1473-3099(18)30110-5. Epub 2018 Mar 23. Review. Erratum in: Lancet Infect Dis. 2018 Apr 27;:.

PMID:
29580819
11.

Predicting the effect of improved socioeconomic health determinants on the tuberculosis epidemic.

Migliori GB, Garcia-Basteiro AL.

Lancet Glob Health. 2018 May;6(5):e475-e476. doi: 10.1016/S2214-109X(18)30189-X. Epub 2018 Mar 23. No abstract available.

12.

Bedaquiline Phenotypic and Genotypic Susceptibility Testing, Work in Progress!

Tiberi S, Cabibbe AM, Tomlins J, Cirillo DM, Migliori GB.

EBioMedicine. 2018 Mar;29:11-12. doi: 10.1016/j.ebiom.2018.02.006. Epub 2018 Feb 8. No abstract available.

13.

Taking forward the Stop TB Partnership and World Health Organization Joint Theme for World TB Day March 24th 2018 - "Wanted: Leaders for a TB-Free World. You can make history. End TB".

Tiberi S, Petersen E, Maeurer M, Ntoumi F, Yeboa-Manu D, Mwaba P, Vilaplana C, Dar O, Bates M, Corrah T, Rao M, Kapata N, Azhar EI, Memish ZA, Mfinanga S, Aseffa A, Ippolito G, Migliori GB, Zumla A.

Int J Infect Dis. 2018 Mar;68:122-124. doi: 10.1016/j.ijid.2018.03.002. Epub 2018 Mar 22. No abstract available.

14.

The World Health Organization standards for tuberculosis care and management.

Gilpin C, Korobitsyn A, Migliori GB, Raviglione MC, Weyer K.

Eur Respir J. 2018 Mar 22;51(3). pii: 1800098. doi: 10.1183/13993003.00098-2018. Print 2018 Mar. No abstract available.

PMID:
29567724
15.

Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.

Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702267. doi: 10.1183/13993003.02267-2017. Print 2018 Mar. No abstract available.

PMID:
29567721
16.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

PMID:
29567720
17.

Professor Massimo Amicosante, 1968-2017.

Goletti D, Montesano C, Mattei M, Migliori GB.

Int J Tuberc Lung Dis. 2018 Feb 1;22(2):236. doi: 10.5588/ijtld.17.0772. No abstract available.

PMID:
29506622
18.

Managing latent tuberculosis infection and tuberculosis in children.

Carvalho I, Goletti D, Manga S, Silva DR, Manissero D, Migliori G.

Pulmonology. 2018 Mar - Apr;24(2):106-114. doi: 10.1016/j.rppnen.2017.10.007. Epub 2018 Mar 2.

19.

New drugs and perspectives for new anti-tuberculosis regimens.

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24.

20.

Multi and extensively drug-resistant pulmonary tuberculosis: advances in diagnosis and management.

Pontali E, Visca D, Centis R, D'Ambrosio L, Spanevello A, Migliori GB.

Curr Opin Pulm Med. 2018 May;24(3):244-252. doi: 10.1097/MCP.0000000000000477.

PMID:
29470252
21.

Adolescents and young adults: a neglected population group for tuberculosis surveillance.

García-Basteiro AL, Schaaf HS, Diel R, Migliori GB.

Eur Respir J. 2018 Feb 21;51(2). pii: 1800176. doi: 10.1183/13993003.00176-2018. Print 2018 Feb. No abstract available.

PMID:
29467211
22.

Combining bedaquiline and delamanid to treat multidrug-resistant tuberculosis.

Tadolini M, Tiberi S, Migliori GB.

Lancet Infect Dis. 2018 May;18(5):480-481. doi: 10.1016/S1473-3099(18)30106-3. Epub 2018 Feb 13. No abstract available.

PMID:
29452940
23.

Point of care diagnostics for tuberculosis.

García-Basteiro AL, DiNardo A, Saavedra B, Silva DR, Palmero D, Gegia M, Migliori GB, Duarte R, Mambuque E, Centis R, Cuevas LE, Izco S, Theron G.

Pulmonology. 2018 Mar - Apr;24(2):73-85. doi: 10.1016/j.rppnen.2017.12.002. Epub 2018 Feb 14.

24.

Diagnostic performances of the Xpert MTB/RIF in Brazil.

Silva DR, Sotgiu G, D'Ambrosio L, Pereira GR, Barbosa MS, Dias NJD, Saderi L, Centis R, Migliori GB.

Respir Med. 2018 Jan;134:12-15. doi: 10.1016/j.rmed.2017.11.012. Epub 2017 Nov 21.

PMID:
29413498
25.

Tuberculosis elimination: a dream or a reality? The case of Oman.

Al Yaquobi F, Al-Abri S, Al-Abri B, Al-Abaidani I, Al-Jardani A, D'Ambrosio L, Centis R, Matteelli A, Manissero D, Migliori GB.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702027. doi: 10.1183/13993003.02027-2017. Print 2018 Jan. No abstract available.

PMID:
29326321
26.

Making optimal use of available anti-tuberculosis drugs: first steps to investigate terizidone.

Alffenaar JWC, Peloquin CA, Migliori GB.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):2. doi: 10.5588/ijtld.17.0632. No abstract available.

PMID:
29297417
27.

Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.

Cabibbe AM, Sotgiu G, Izco S, Migliori GB.

Eur Respir J. 2017 Dec 28;50(6). pii: 1702292. doi: 10.1183/13993003.02292-2017. Print 2017 Dec. No abstract available.

PMID:
29284689
28.

Respiratory infection: insights from Assembly 10 of the European Respiratory Society 2017 Annual Congress.

Garcia-Basteiro AL, Wong E, Van Oort PM, Cilloniz C, Migliori GB, Singanayagam A.

J Thorac Dis. 2017 Nov;9(Suppl 16):S1559-S1562. doi: 10.21037/jtd.2017.11.39. No abstract available.

29.

Prevention of tuberculosis transmission through medical surveillance systems.

Sotgiu G, Migliori GB.

Lancet Public Health. 2017 Oct;2(10):e439-e440. doi: 10.1016/S2468-2667(17)30179-2. Epub 2017 Oct 3. No abstract available.

30.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):132-141. doi: 10.1016/j.rppnen.2017.10.005. Epub 2017 Dec 8.

31.

Current use and acceptability of novel diagnostic tests for active tuberculosis: a worldwide survey.

Amicosante M, D'Ambrosio L, Munoz M, Mello FCQ, Tebruegge M, Chegou NN, Seghrouchni F, Centis R, Goletti D, Bothamley G, Migliori GB; TB Diagnostic Survey Working Group.

J Bras Pneumol. 2017 Sep-Oct;43(5):380-392. doi: 10.1590/S1806-37562017000000219. English, Portuguese.

32.

Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence.

Pontali E, Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2017 Nov 16;50(5). pii: 1701462. doi: 10.1183/13993003.01462-2017. Print 2017 Nov. No abstract available.

PMID:
29146605
33.

Bedaquiline: how better to use it.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701670. doi: 10.1183/13993003.01670-2017. Print 2017 Nov. No abstract available.

PMID:
29122921
34.

Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.

Falzon D, Migliori GB, Jaramillo E, Weyer K, Joos G, Raviglione M; Global Task Force on digital health for TB.

Eur Respir J. 2017 Nov 9;50(5). pii: 1701632. doi: 10.1183/13993003.01632-2017. Print 2017 Nov. No abstract available.

PMID:
29122920
35.

Rifabutin: Is it useful in the treatment of multidrug-resistant tuberculosis?

Tiberi S, D'Ambrosio L, Centis R, Migliori GB.

Int J Infect Dis. 2017 Dec;65:133-134. doi: 10.1016/j.ijid.2017.10.019. Epub 2017 Nov 6. No abstract available.

36.

Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.

Luzzati R, Migliori GB, Zignol M, Cirillo DM, Maschio M, Tominz R, Ventura G, Patussi V, D'Ambrosio L, Centis R, Michieletto F, Trovato A, Salton F, Busetti M, Di Santolo M, Raviglione M, Confalonieri M.

Eur Respir J. 2017 Nov 2;50(5). pii: 1701414. doi: 10.1183/13993003.01414-2017. Print 2017 Nov. No abstract available.

PMID:
29097434
37.

Roadmap for Tuberculosis Elimination in Latin America and the Caribbean.

Torres-Duque CA, Fuentes Alcalá ZM, Rendón A, Migliori GB.

Arch Bronconeumol. 2018 Jan;54(1):7-9. doi: 10.1016/j.arbres.2017.07.004. Epub 2017 Oct 6. English, Spanish. No abstract available.

38.

X-Rays from the Location of the Double-humped Transient ASASSN-15lh.

Margutti R, Metzger BD, Chornock R, Milisavljevic D, Berger E, Blanchard PK, Guidorzi C, Migliori G, Kamble A, Lunnan R, Nicholl M, Coppejans DL, Dall'Osso S, Drout MR, Perna R, Sbarufatti B.

Astrophys J. 2017 Feb 10;836(1). pii: 25. doi: 10.3847/1538-4357/836/1/25. Epub 2017 Feb 6.

39.

Post-implementation blues: the unfulfilled potential of Xpert.

Tiberi S, Pontali E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Oct 1;21(10):1073. doi: 10.5588/ijtld.17.0478. No abstract available.

PMID:
28911347
40.

Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic science.

Alffenaar JC, Migliori GB, Gumbo T.

Lancet Infect Dis. 2017 Sep;17(9):898. doi: 10.1016/S1473-3099(17)30449-8. No abstract available.

PMID:
28845791
41.

Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.

D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M, Rendon A, Esposito S, Migliori GB.

J Thorac Dis. 2017 Jul;9(7):2093-2101. doi: 10.21037/jtd.2017.06.16. Review.

42.

Understanding the multidrug-resistant tuberculosis epidemic in China.

Centis R, D'Ambrosio L, Migliori GB.

Int J Tuberc Lung Dis. 2017 Sep 1;21(9):955. doi: 10.5588/ijtld.17.0438. No abstract available.

PMID:
28826442
43.

Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.

Maryandyshev A, Pontali E, Tiberi S, Akkerman O, Ganatra S, Sadutshang TD, Alffenaar JW, Amale R, Mullerpattan J, Topgyal S, Udwadia ZF, Centis R, D'Ambrosio L, Sotgiu G, Migliori GB.

Emerg Infect Dis. 2017 Oct;23(10). doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.

44.

A new free-cost e-service supporting clinicians to manage their difficult-to-treat tuberculosis cases: The European Respiratory Society-World Health Organization tuberculosis Consilium.

D'Ambrosio L, Tadolini M, Centis R, Chalmers JD, Migliori GB.

Indian J Med Res. 2017 Mar;145(3):261-263. doi: 10.4103/ijmr.IJMR_37_17. No abstract available.

45.

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.

Caminero JA, Piubello A, Scardigli A, Migliori GB.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700648. doi: 10.1183/13993003.00648-2017. Print 2017 Jul. No abstract available.

PMID:
28679614
46.

Tuberculosis control, and the where and why of artificial intelligence.

Doshi R, Falzon D, Thomas BV, Temesgen Z, Sadasivan L, Migliori GB, Raviglione M.

ERJ Open Res. 2017 Jun 21;3(2). pii: 00056-2017. doi: 10.1183/23120541.00056-2017. eCollection 2017 Apr. Review.

47.

Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.

de Rosa F, Ridolfi L, Fiammenghi L, Petrini M, Granato AM, Ancarani V, Pancisi E, Soldati V, Cassan S, Bulgarelli J, Framarini M, Tauceri F, Migliori G, Brolli C, Gentili G, Petracci E, Nanni O, Riccobon A, Ridolfi R, Guidoboni M.

Melanoma Res. 2017 Aug;27(4):351-357. doi: 10.1097/CMR.0000000000000356.

PMID:
28654547
48.

Cross-border collaboration for improved tuberculosis prevention and care: policies, tools and experiences.

Dara M, Sulis G, Centis R, D'Ambrosio L, de Vries G, Douglas P, Garcia D, Jansen N, Zuroweste E, Migliori GB.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):727-736. doi: 10.5588/ijtld.16.0940.

PMID:
28633696
49.

Tuberculosis, alcohol and tobacco: Dangerous liaisons.

Santos-Silva AF, Migliori GB, Duarte R.

Rev Port Pneumol (2006). 2017 Jul - Aug;23(4):177-178. doi: 10.1016/j.rppnen.2017.05.001. Epub 2017 May 31. No abstract available.

50.

Standard operating procedures for tuberculosis care.

Solovic I, Abubakar I, Sotgiu G, Dara M, Goletti D, Duarte R, Aliberti S, de Benedictis FM, Ward B, Teixeira V, Gratziou C, Migliori GB.

Eur Respir J. 2017 Jun 1;49(6). pii: 1700515. doi: 10.1183/13993003.00515-2017. Print 2017 Jun. No abstract available.

PMID:
28572129

Supplemental Content

Loading ...
Support Center